We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 11 oktober 2017

The Lancet: [Comment] Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?

[Comment] Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?
Annually, more than 950 000 people are diagnosed with gastric or oesophagogastric junction cancer1—the third most lethal cancer worldwide2—for which there is a considerable unmet clinical need. Blockade of immune checkpoints has been successfully integrated into standard treatment regimens for several solid tumours.3 The ATTRACTION-2 study by Yoon-Koo Kang and colleagues4 in The Lancet is, to my knowledge, the first randomised, placebo-controlled, phase 3 trial of immune checkpoint blockade in gastrointestinal cancers.
Read more

[Department of Error] Department of Error
Ganatra B, Gerdts C, Rossier C, et al. Global, regional, and subregional classification of abortions by safety, 2010–14: estimates from a Bayesian hierarchical model. Lancet 2017; doi:http://dx.doi.org/10.1016/S0140-6736(17)31794-4—In this Article (published Online First on Sept 27, 2017), the sentence in the Discussion "Although eastern Asia appeared to be similar to developed regions, fewer than one in two abortions elsewhere in Asia, and about one in four abortions in Africa, were safe" should be "Although eastern Asia was similar to developed regions, fewer than one in two abortions in south-central Asia and about one in four abortions in Africa were safe".
Read more

[Comment] Treaty to prohibit nuclear weapons: towards safeguarding humanity
Escalating tensions around nuclear weapons in North Korea remind us that humanity remains vulnerable to their use by design, miscalculation, or accident. About 15 000 warheads exist today, of which nearly 1800 warheads are on alert and ready for use at short notice.1
Read more

[Department of Error] Department of Error
Kirchhof P. The future of atrial fibrillation management: intergrated care and stratified therapy. Lancet 2017; published online April 28. http://dx.doi.org/10.1016/S0140-6736(17)31072-3—In table 4 of this Seminar (), the dose of edoxaban should be 60 mg once daily. This correction has been made to the online version as of Oct 10, and will be made to the printed Article.
Read more

[Comment] Clemastine fumarate for promotion of optic nerve remyelination
The regulatory approval of 15 disease-modifying medications to reduce inflammatory lesion activity in relapsing multiple sclerosis illustrates the dramatic progress made in the treatment of this frequently disabling condition. None of these medications, however, directly promotes repair of the damaged CNS. As a result, therapies to prevent accumulation of permanent disability and, especially, to reverse pre-existing disability represent major unmet needs.
Read more